Physician profile
Cesar Ang
NPI 1225010218
$3,258.33
in general payments reported to CMS, 2019-2025
32 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $517 · 2021: $66.89 · 2022: $485 · 2023: $625 · 2024: $536 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $575.72 | 2019-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $389.10 | 2022-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Amgen INC. | $285.24 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $259.98 | 2020-2024 | Breztri, Andexxa |
| Exact Sciences Corporation | $241.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $219.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $218.32 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $182.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.28 | 2019-2022 | |
| Astellas Pharma US INC | $150.42 | 2019-2020 | |
| Sanofi Pasteur INC. | $74.75 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $56.90 | 2019-2020 | |
| Lilly USA, LLC | $56.68 | 2019-2022 | |
| Medtronic, INC. | $56.46 | 2022-2025 | Inceptiv |
| Novartis Pharmaceuticals Corporation | $36.80 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $27.96 | 2019 | |
| Abbvie INC. | $25.57 | 2022 | |
| Ibsa Pharma INC. | $24.05 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.74 | 2019 | |
| Cranial Technologies, INC | $19.92 | 2025 | Doc Band |
| Biogen, INC. | $19.88 | 2024 | Spinraza |
| Biohaven Pharmaceutical Holding Company LTD. | $18.10 | 2022 | |
| Boston Scientific Corporation | $17.88 | 2020 | |
| Radius Health, INC. | $16.15 | 2019 | |
| Mylan Specialty L.P. | $15.43 | 2019 | |
| Bausch Health US, LLC | $15.34 | 2020 | |
| Eisai INC. | $15.28 | 2020 | |
| Novo Nordisk INC | $14.79 | 2019 | |
| Allergan, INC. | $14.63 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.02 | 2023 | Uptravi, Opsumit |
| Biodelivery Sciences International, INC. | $11.08 | 2019 | |
| Organon LLC | $9.33 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Ang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.